FDA Approves NovoCure's Optune Pax for Locally Advanced Pancreatic Cancer, First New Treatment in Nearly 30 Years
核心洞察
The FDA approved NovoCure (搜索)'s Optune Pax (搜索) device for treating locally advanced pancreatic cancer (搜索), marking the first new treatment option for this indication in nearly three decades.
The portable device delivers Tumor Treating Fields (搜索) therapy through wearable arrays and is used in combination with gemcitabine and nab-paclitaxel chemotherapy.
Phase 3 PANOVA-3 trial results showed median overall survival improved to 16.2 months compared to 14.2 months with chemotherapy alone, representing a two-month survival benefit.
The U.S. Food and Drug Administration has approved NovoCure (搜索)'s Optune Pax (搜索) device for the treatment of locally advanced pancreatic cancer (搜索), representing the first new therapeutic option for this indication in nearly 30 years. The regulatory milestone sent NovoCure (NASDAQ: NVCR) shares soaring more than 30% in after-hours trading Wednesday.
Revolutionary Tumor Treating Fields Technology
Optune Pax (搜索) is a portable therapeutic device that delivers Tumor Treating Fields (搜索) (TTFields) noninvasively through wearable arrays. The system uses alternating electric fields to disrupt cancer cell division, interfering with tumor growth and triggering cancer cell death while minimizing damage to healthy tissue. The device is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.
"This is a proud moment for NovoCure (搜索) and we look forward to bringing Optune Pax (搜索) to patients and the healthcare providers who care for them," said Frank Leonard, NovoCure's CEO.
Phase 3 Trial Demonstrates Survival Benefit
The FDA's approval was supported by data from the PANOVA-3 trial, an open-label Phase 3 study that evaluated Optune Pax (搜索) in combination with gemcitabine and nab-paclitaxel against treatment with gemcitabine and nab-paclitaxel alone in 571 patients with locally advanced pancreatic cancer (搜索).
The trial demonstrated a clinically meaningful improvement in overall survival. Median overall survival reached 16.2 months for patients receiving the combination therapy, compared with 14.2 months for those receiving chemotherapy alone, representing a two-month improvement with a hazard ratio of 0.82 (p=0.039).
Additionally, the time to pain progression was significantly extended to 15.2 months in the combination group, compared with 9.1 months in the control group. The study also showed higher one-year survival rates for patients treated with the combination of TTFields therapy and standard chemotherapy.
Safety Profile and Clinical Impact
Safety results were broadly comparable between the treatment and control groups, reinforcing the therapy's tolerability profile. Device-related skin reactions occurred in 76.3% of patients, with most reactions classified as Grade 1 or 2.
Dr. Vincent Picozzi, a PANOVA-3 trial investigator, noted that Optune Pax (搜索) "has the potential to be practice changing for the treatment of patients with locally advanced pancreatic cancer (搜索)."
Market Response and Commercial Potential
Following the FDA approval announcement, NVCR shares jumped to $13.80 in extended trading, after rising more than 50% earlier in after-hours sessions. The sharp increase reflects strong investor confidence in the commercial potential of Optune Pax (搜索) and its role in expanding pancreatic cancer (搜索) treatment options.
With this approval, NovoCure (搜索) strengthens its oncology portfolio and positions Optune Pax (搜索) as a promising new standard of care in advanced pancreatic cancer (搜索) treatment, addressing urgent unmet medical needs in this challenging therapeutic area.